Summary: In 8246 patients with type 2 diabetes and atherosclerotic cardiovascular disease, ertugliflozin was non-inferior to placebo for major adverse cardiovascular events (11.9% in both groups; hazard ratio 0.97; 95.6% CI 0.85 to 1.11) over a mean of 3.5 years. Superiority was not shown for cardiovascular death or heart failure hospitalisation (hazard ratio 0.88; 95.8% CI 0.75 to 1.03).
PICO Summary
| Element | Detail |
|---|---|
| Population | 8246 patients with type 2 diabetes and atherosclerotic cardiovascular disease; multicentre, double-blind, randomised, placebo-controlled trial; mean follow-up 3.5 years. |
| Intervention | Ertugliflozin 5 mg or 15 mg once daily, with the two dose groups pooled for analysis (n=5499). |
| Comparison | Placebo once daily (n=2747). |
| Outcome | Major adverse cardiovascular events (cardiovascular death, non-fatal myocardial infarction or non-fatal stroke): 653 of 5493 (11.9%) vs 327 of 2745 (11.9%); HR 0.97 (95.6% CI 0.85 to 1.11); p<0.001 for non-inferiority (margin 1.3). Cardiovascular death or heart failure hospitalisation: 444 of 5499 (8.1%) vs 250 of 2747 (9.1%); HR 0.88 (95.8% CI 0.75 to 1.03); p=0.11 for superiority. Cardiovascular death: HR 0.92 (95.8% CI 0.77 to 1.11). Renal death, renal replacement therapy or doubling of serum creatinine: HR 0.81 (95.8% CI 0.63 to 1.04). Amputation: 2.0% (5 mg) and 2.1% (15 mg) vs 1.6%. |
Expert Commentary
My verdict is neutral. VERTIS CV did what a safety trial is asked to do and no more. In 8246 patients with type 2 diabetes and established atherosclerotic cardiovascular disease, major adverse cardiovascular events occurred in 11.9% of both groups over a mean of 3.5 years (hazard ratio 0.97; 95.6% CI 0.85 to 1.11), which met the non-inferiority margin of 1.3. The first key secondary outcome, cardiovascular death or heart failure hospitalisation, was not significantly reduced (hazard ratio 0.88; 95.8% CI 0.75 to 1.03; p=0.11), and the interval for the renal composite also crossed 1 (hazard ratio 0.81; 95.8% CI 0.63 to 1.04). The limitation I weigh most is that the abstract does not report heart failure hospitalisation on its own, the outcome on which this drug class has been most consistent, so it cannot be judged here. Amputations were numerically more frequent with ertugliflozin (2.0% and 2.1% against 1.6%). The trial was funded by the manufacturers. Can I use this with my patients? Ertugliflozin can be regarded as safe from a cardiovascular standpoint in patients like these, but I would not present it as a drug proven to prevent cardiovascular events. Where cardiovascular or renal protection is the aim, an agent with a positive outcome trial should be preferred.
References
Cannon CP, Pratley R, Dagogo-Jack S, et al. Cardiovascular outcomes with ertugliflozin in type 2 diabetes. N Engl J Med. 2020;383(15):1425-1435. doi:10.1056/NEJMoa2004967. PMID: 32966714.

